SABA/ICS prn combo for asthma: AIRSUPRA (albuterol/budesonide)

As of January 2023, AIRSUPRA (albuterol/budesonide), has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.

AIRSUPRA (180mcg albuterol/160mcg budesonide) significantly reduced the risk of severe exacerbations compared to albuterol in patients with moderate to severe asthma when used as an as-needed rescue medication in response to symptoms.

Albuterol rescue inhalers available prior to 2023 can alleviate acute symptoms, but do not treat the underlying inflammation in asthma. The approval of AIRSUPRA means that for the first time, adults with asthma in the US have a rescue treatment to manage both their symptoms and the inflammatory nature of their disease.

References:

https://www.astrazeneca-us.com/content/az-us/media/press-releases/2023/airsupra-pt027-approved-in-the-us-for-asthma.html